by Aleksandar Nikolajevic | Aug 27, 2026 | Newsletter
August 2026 Newsletter Summary: New antibody approved: Clesrovimab (Enflonsia®) received EU approval in April 2026 — the third prophylactic RSV antibody after Palivizumab and Nirsevimab. Weight-independent dosing: Fixed 105 mg dose for all newborns and infants, unlike...
by Aleksandar Nikolajevic | Aug 5, 2026 | Institute
Institute of Virology Innsbruck Joins the Global Virus Network as Austria’s First Center of Excellence The Institute of Virology at the Medical University of Innsbruck has been accepted into the Global Virus Network (GVN) as a Center of Excellence. It is the...
by Aleksandar Nikolajevic | Jul 31, 2026 | Newsletter
July 2026 Newsletter Summary: Geographic risk: Sandfly-borne phleboviruses (SFNV, SFSV, TOSV) circulate widely across the Mediterranean, including Italy, Spain, Croatia and Greece; the main transmission season runs from May to October. Travel-associated: The vector...
by Aleksandar Nikolajevic | Jul 24, 2026 | Press Coverage
Press Article FEATURED IN Tiroler Tageszeitung on „Risiken um die Tigermücke werden unterschätzt”: Experten warnen vor importiertem Insekt Summary: A Tiroler Tageszeitung feature warning that the risks associated with the Asian tiger mosquito are...
by Aleksandar Nikolajevic | Jul 24, 2026 | Press Coverage
Press Article FEATURED IN EenVandaag on Teek met levensgevaarlijk TBE-virus volop in vakantiehotspots onder Nederlanders: Erika lag 4 dagen in coma Summary: A feature by Dutch current affairs programme EenVandaag on the risk of tick-borne encephalitis (TBE) for...
